Alergia alimentar

Última revisão: 6 Nov 2022
Última atualização: 12 Ago 2022

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • ingestão de leite, ovos, nozes, peixe, marisco, trigo ou soja
  • sintomas reprodutíveis
  • rubor, urticária ou angioedema cutâneo
  • espirros, rinorreia ou congestão nasal
  • dispneia, taquipneia, sibilância, tosse ou cianose
  • rouquidão, estridor ou sensação de sufocamento
  • náuseas e vômitos
  • cólica ou distensão abdominal
  • diarreia
  • hiperemia conjuntival ou lacrimejamento
  • edema periorbital
  • início abrupto dos sintomas
  • reação causada por uma pequena quantidade de alimento
  • presença de outras doenças alérgicas
  • edema laríngeo
Mais principais fatores diagnósticos

Outros fatores diagnósticos

  • taquicardia ou bradicardia
  • reação exacerbada por exercícios ou esforço físico
  • ingestão de medicamentos ou de bebidas alcoólicas antes da reação
  • arritmia cardíaca
  • hipotensão
Outros fatores diagnósticos

Fatores de risco

  • história familiar de alergia alimentar
  • dermatite atópica
  • neonatos
  • exposição perinatal a óleo de amendoim
Mais fatores de risco

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • imunoensaio da imunoglobulina E (IgE) específica in vitro
  • teste alérgico cutâneo por puntura ("prick test")
Mais primeiras investigações a serem solicitadas

Investigações a serem consideradas

  • testes de desencadeamento alimentar
  • diagnósticos resolvidos por componentes
Mais investigações a serem consideradas

Novos exames

  • testes de adesivo atópico

Algoritmo de tratamento

Aguda

reação anafilática

sintomas cutâneos

broncoespasmo

rinoconjuntivite

Contínua

após a estabilização

Colaboradores

Autores

A. Wesley Burks, MD
A. Wesley Burks

Curnen Distinguished Professor and Chair

Department of Pediatrics

University of North Carolina

Chapel Hill

NC

Declarações

AWB receives grant support to his institution from the National Institutes of Health and the Burroughs Wellcome Fund; royalties from UpToDate; consulting honorariums from Astella Pharma Global Development, Allergy Therapeutics (UK) Ltd, DBV Technologies, Kaléo, N-Fold, LLC, ALK-Abelló, Inc and UKKO, Inc as well as Aimmune Therapeutics, Consortia TX, Inc., and Prota Therapeutics for his service on their respective Scientific Advisory Boards. AWB has consulted for the following companies (which are all now expired): Biomerica, Inc., Evelo Biosciences/Epiva, Genentech, Insys Therapeutics, PPD Development, Sanofi US Services, Valeant Pharmaceuticals North America, LLC, LEK Consulting, LLC, Hycor Biomedical. AWB has received payments for speaking at the Gordon Research Conferences, the Pediatric Allergy and Asthma Meeting, and the American College of Allergy Asthma and Immunology. AWB is a minority stockholder of both Allertein and Mastcell Pharmaceuticals stock. These interests do not directly relate to the article but are being shared for full disclosure. AWB is an author of references cited in this topic.

J. Andrew Bird, MD

Associate Professor

Department of Pediatrics

Division of Allergy and Immunology

University of Texas Southwestern Medical Center

Dallas

TX

Declarações

JAB has received personal fees from Abbot, grants and personal fees from Aimmune, personal fees from AllerGenis, personal fees from Allergy Therapeutics, personal fees from Before Brands, grants and personal fees from DBV Technologies, grants and personal fees from FARE, personal fees from HAL Allergy, grants and personal fees from Novartis, personal fees from Nutricia, personal fees from Prota Therapeutics, grants from Astellas, grants from Genentech, grants from NIH-NIAID, grants from Regeneron; and Vedanta Biosciences, Independent Study Monitor (uncompensated).

Revisores

Justin Skripak, MD

Assistant Professor of Pediatric Allergy and Immunology

Mount Sinai School of Medicine

New York

NY

Declarações

JS declares that he has no competing interests.

Hugh A. Sampson, MD

Professor of Pediatrics

Mount Sinai School of Medicine

New York

NY

Declarações

HAS holds a 4% interest in a biotech company, Allertein Pharmaceuticals LLC, which is developing an engineered recombinant protein vaccine for peanut allergy, and 45% interest in a virtual company, Herbal Springs LLC, that holds a patent application on an herbal product for treating asthma and another for treating food allergy. HAS is an author of a number of references cited in this topic.

Adam Fox, MA(Hons) Cantab., MSc, MBBS, DCH, FRCPCH, FHEA, Dip. Allergy

Consultant and Honorary Senior Lecturer in Paediatric Allergy

Evelina Children's Hospital

Guy's & St Thomas' Hospitals NHS Foundation Trust

London

UK

Declarações

AF declares that he has no competing interests.

  • Alergia alimentar images
  • Diagnósticos diferenciais

    • Dermatite atópica
    • Urticária
    • Síndrome auriculotemporal
    Mais Diagnósticos diferenciais
  • Diretrizes

    • BSACI guidelines for the management of egg allergy
    • A consensus approach to the primary prevention of food allergy through nutrition: guidance from the American Academy of Allergy, Asthma, and Immunology; American College of Allergy, Asthma, and Immunology; and the Canadian Society for Allergy and Clinical Immunology
    Mais Diretrizes
  • Folhetos informativos para os pacientes

    Alergia alimentar: o que é?

    Alergia alimentar: que tratamentos estão disponíveis?

    Mais Folhetos informativos para os pacientes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal